There is greater genetic diversity in Africa than in any other continent, studies have consistently shown. Such variations have the potential to reveal insights that enable the development of treatments for health conditions that affect Africans and non-Africans alike. One such project is already underway and making rapid progress: Nigerian health tech startup 54gene, billed as “the world’s first pan-African biobank,” with a mission to address some of the continent’s most serious health challenges. 54gene makes the genetic material in its biobank available to pharma companies and academic and clinical researchers to facilitate the development of healthcare solutions. Core targets for treatment include cancer, cardiovascular disease, and neuro-degenerative disease.